1. A 58-year-old patient taking metformin and glipizide presents for a 3-month diabetes check. Their A1c is 6.8%, but they report experiencing two hypoglycemic episodes weekly. Which modification to the plan of care is most appropriate?
Answer: C
Modifying a diabetes care plan often involves de-escalating therapy when safety concerns arise. Although the patient's A1c is at target, experiencing hypoglycemia risk twice weekly is dangerous and requires immediate intervention. Sulfonylureas like glipizide stimulate insulin secretion independent of glucose levels, making them a primary culprit for hypoglycemia. Discontinuing glipizide and starting an SGLT2 inhibitor like empagliflozin maintains glycemic control while virtually eliminating the hypoglycemia risk. Option A is incorrect because metformin rarely causes hypoglycemia; reducing it targets the wrong medication. Option B is incorrect because basal insulin also carries a significant risk of hypoglycemia and is not indicated here. Option D is incorrect because maintaining a regimen that causes frequent hypoglycemia ignores a critical safety issue and violates the standard of care for middle adults.
2. A 42-year-old female was diagnosed with type 2 diabetes six months ago. Her body mass index is 21 kg/m2. Despite strict adherence to metformin and diet, her A1C has increased to 8.9%. Which of the following is the most appropriate action?
Answer: A
When a middle-aged adult with a normal body mass index rapidly fails oral therapy despite adherence, you must suspect Latent Autoimmune Diabetes in Adults (LADA). Option A correctly targets this differential diagnosis by checking for autoantibodies. Options B and C inappropriately double down on type 2 diabetes treatments, which will fail if she is experiencing autoimmune beta-cell destruction. Option D tests for insulin resistance, which is characteristic of type 2 diabetes, not the insulin deficiency seen in LADA.
3. A 22-year-old female presents to the emergency department with an arterial pH of 7.21 and positive serum ketones. What underlying cellular defect explains this specific acute complication?
Answer: C
Diabetic ketoacidosis is driven by an absolute insulin deficiency, which normally suppresses fat breakdown. Without insulin, uninhibited lipolysis releases free fatty acids that the liver converts into ketones, lowering the arterial pH. Options A and B contribute to hyperglycemia in Type 2 diabetes but do not directly cause severe ketogenesis. Option D describes the hyperosmolar hyperglycemic state, a complication of Type 2 diabetes where residual endogenous insulin is sufficient to prevent lipolysis and ketosis but not hyperglycemia.
4. A 55-year-old male with uncontrolled type 2 diabetes requires basal insulin initiation. He has a high-deductible health plan and expresses concern about the cost of branded insulin glargine. His fasting glucose averages 180 mg/dL. Which prescription is the most cost-effective and clinically equivalent alternative?
Answer: A
For patients requiring basal insulin who face high out-of-pocket costs, an interchangeable biosimilar insulin glargine offers the exact same peakless, 24-hour basal coverage as the reference branded product but at a significantly lower price point. This directly addresses the financial constraints of his high-deductible health plan without compromising his glycemic control. While human NPH and regular insulin vials are inexpensive, they have distinct peaks of action that increase the risk of hypoglycemia and fail to provide true 24-hour basal coverage. Branded concentrated insulins like degludec provide excellent basal coverage but remain cost-prohibitive, which would likely lead to medication nonadherence in this specific financial scenario.
5. An FNP directs a community health center that recently received a limited grant for diabetes management. The FNP allocates the majority of the funds to a neighborhood with high poverty and low health literacy rather than dividing the funds equally across all districts. Which ethical concept justifies this decision?
Answer: C
Health equity focuses on eliminating systemic barriers and providing resources according to specific population needs, rather than distributing them equally regardless of baseline health status. Option C is correct because directing the limited grant for diabetes management to a neighborhood with high poverty and low health literacy directly addresses the underlying social determinants of health. Option A describes equality, not equity; giving equal shares ignores the disproportionate burden faced by the disadvantaged neighborhood. Option B incorrectly applies autonomy; while community input is valuable, simply handing over funds without a targeted clinical strategy does not fulfill the FNP's duty to improve outcomes. Option D reflects utilitarianism, which aims for the greatest good for the greatest number but often leaves marginalized, high-need populations behind if they are harder or more expensive to reach.
6. A 14-year-old female with a BMI at the 96th percentile presents with darkened, thickened skin on her posterior neck. Which pathophysiologic mechanism primarily drives her current clinical presentation?
Answer: B
Acanthosis nigricans and severe obesity in youth strongly indicate peripheral insulin resistance, the hallmark pathogenesis of Type 2 diabetes. The body compensates with hyperinsulinemia before beta cells eventually fail. Options A and D describe the absolute insulin deficiency and autoimmune destruction characteristic of Type 1 diabetes, which does not typically present with acanthosis nigricans. Option C describes maturity-onset diabetes of the young, a genetic defect in insulin secretion that typically presents without severe obesity or profound insulin resistance.
7. A 48-year-old female with type 2 diabetes had an A1c of 8.8% one month ago. She was started on empagliflozin at that time and returns today for a routine follow-up. Which action is most appropriate regarding her lab work?
Answer: D
Hemoglobin A1c reflects average blood glucose over a three-month period due to the lifespan of red blood cells. When adjusting or initiating new diabetes medications, evaluating pharmacotherapeutic efficacy requires waiting until this cycle completes. Option D is correct because scheduling the test in eight weeks aligns with the three-month mark from initiation. Option A is incorrect because checking today only captures one month of therapy, yielding a falsely elevated result. Option B is incorrect because waiting six months delays necessary therapeutic adjustments. Option C is incorrect because fasting glucose does not reflect overall treatment efficacy.
8. A 28-year-old Asian American male presents for a routine wellness examination. He has a BMI of 24.2 and reports feeling entirely well with no polyuria or polydipsia. His medical history is unremarkable, but he notes his father has type 2 diabetes. Which action should the nurse practitioner take?
Answer: A
Clinical guidelines recommend screening for asymptomatic adults of any age who are overweight and have one or more risk factors. For Asian Americans, the overweight threshold is lowered to a BMI of 23 or higher due to increased central adiposity risks. Because this patient meets the ethnic BMI cutoff and has a first-degree relative with diabetes, he requires immediate screening. Delaying until age 35 ignores the specific ethnic guidelines and his family history. Recommending lifestyle changes without baseline testing or waiting for the next annual visit inappropriately delays the potential diagnosis and management of prediabetes or diabetes.
9. A 50-year-old male with newly diagnosed Type 2 diabetes demonstrates a diminished insulin response following oral glucose load. Which pathophysiologic mechanism directly contributes to this specific finding?
Answer: C
The incretin effect refers to the amplified insulin response to oral glucose compared to intravenous glucose. In Type 2 diabetes, a blunted incretin effect occurs due to decreased secretion and beta-cell responsiveness to GLP-1 and GIP. Option A describes the renal handling of glucose, which contributes to hyperglycemia but does not explain the differential oral glucose response. Option B contributes to fasting hyperglycemia through excessive glucose production. Option D describes the rapid autoimmune destruction seen in Type 1 diabetes, not Type 2.
10. A 45-year-old Hispanic male has an average clinic blood pressure of 134/84 mmHg and a home average of 132/82 mmHg. His calculated 10-year ASCVD risk is 4% and he has no history of cardiovascular disease.
Answer: C
Under the ACC/AHA guidelines, this patient has Stage 1 hypertension. Because his ASCVD risk is less than 10% and he lacks clinical cardiovascular disease or diabetes, the recommended initial management is intensive lifestyle modification rather than medication. Recommending a thiazide diuretic, calcium channel blocker, or ACE inhibitor would be premature at this stage. Pharmacologic therapy is only indicated for Stage 1 hypertension if the patient has an ASCVD risk of 10% or greater, diabetes, chronic kidney disease, or known cardiovascular disease.
11. A 55-year-old male with type 2 diabetes presents for follow-up. He started on lisinopril 10 mg daily 2 weeks ago. His blood pressure today is 132/82 mmHg. His baseline Cr was 1.0 mg/dL, and today Cr is 1.25 mg/dL. His serum potassium is 4.8 mEq/L. Which action is most appropriate?
Answer: A
A bump in serum creatinine up to 30 percent is expected when initiating an ACE inhibitor due to the desired reduction in intraglomerular pressure from efferent arteriole dilation. The patient's baseline creatinine was 1.0, and the current value of 1.25 represents a 25 percent increase, which falls well within the acceptable safety threshold. Continuing the medication and monitoring is the most appropriate action. Decreasing the dose or discontinuing the drug is unnecessary, as doing so would deprive this diabetic patient of essential renal and cardiovascular protection. Ordering a renal artery ultrasound is premature and not indicated unless the creatinine rises over 30 percent or the patient develops refractory hypertension despite multiple agents.
12. A 60-year-old female with type 2 diabetes takes glipizide 10 mg daily. She is starting her clear liquid diet today for a colonoscopy tomorrow. What should the FNP advise regarding her medication?
Answer: D
When a patient transitions to a clear liquid diet for bowel preparation, their caloric intake drops significantly. Glipizide is a sulfonylurea that stimulates insulin release regardless of glucose intake, placing the fasting patient at high risk for severe hypoglycemia. Therefore, Option D is correct; the medication must be held on the day of the clear liquid diet and the morning of the procedure. Option A is incorrect because taking the full dose without solid food will almost certainly cause hypoglycemia. Option B is incorrect because even a reduced dose of a secretagogue is unsafe during a strict fast. Option C is incorrect as doubling the dose would be dangerous and counterintuitive when caloric intake is drastically reduced. Normal dosing typically resumes after the procedure once the patient tolerates a regular diet.
13. An 80-year-old female with type 2 diabetes is currently taking metformin 1000 mg daily. Her recent comprehensive metabolic panel reveals her eGFR has declined to 28 mL/min/1.73 m2.
Answer: A
Metformin is contraindicated and must be discontinued when the eGFR falls below 30 mL/min/1.73 m2 due to the significantly increased risk of lactic acidosis. Option B is incorrect because a dose reduction (typically by half) is only appropriate when the eGFR is between 30 and 45 mL/min/1.73 m2. Option C is unsafe given the severe renal impairment. Option D is incorrect because sulfonylureas also carry exceptionally high risks of prolonged hypoglycemia in older adults with severe chronic kidney disease and should generally be avoided.
14. A 45-year-old female presents for a routine wellness exam. During the physical assessment, you discover a palpable 1.5 cm nodule in the right thyroid lobe. The patient is completely asymptomatic. Which of the following is the most appropriate next step?
Answer: A
For a palpable thyroid nodule, the initial diagnostic step is to assess both function and structure by ordering a serum TSH and a dedicated ultrasound. Option B is premature because biopsy indications depend heavily on sonographic features and exact size. Option C is only indicated if the initial TSH is subnormal, which helps identify a hyperfunctioning nodule. Option D inappropriately delays necessary diagnostic evaluation for a newly discovered palpable mass.
15. A 78-year-old female presents with three months of progressive memory loss, apathy, and generalized weakness. Her daughter suspects dementia. Vitals show a HR 58 and BP 138/88. She denies cold intolerance or weight gain.
Answer: A
Elderly patients with hypothyroidism frequently present atypically, exhibiting cognitive impairment, apathy, and generalized weakness rather than the classic symptoms of weight gain and cold intolerance seen in younger populations. When evaluating an older adult for suspected dementia, checking a thyroid-stimulating hormone level is a critical first step to rule out highly reversible endocrine abnormalities. Initiating a trial of donepezil or referring to neurology for cognitive decline evaluation is premature until organic, treatable causes of memory loss are fully excluded. Similarly, prescribing a selective serotonin reuptake inhibitor daily for late-life depression without first assessing thyroid function can lead to unnecessary polypharmacy and fail to address the root physiological cause of the patient's symptoms.
